Heart failure & cardiomyopathies
Redefining response to cardiac resynchronization therapy: a post hoc analysis of the MORE-CRT MPP trial
Authors' conclusion
Delayed responders demonstrated similarly favourable clinical outcomes to early responders over the duration of follow-up.
Study context
- Population
- Patients receiving conventional biventricular pacing only in the MORE-CRT MPP trial
- Participants
- 2,732 patients
- Comparison
- Early vs delayed vs non-responders to cardiac resynchronization therapy (CRT)
- Primary endpoint
- HF hospitalization or death (event-free survival)
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
HF hospitalization or death (event-free survival)
- Non-responders vs Early responders
- shorter event-free survival 52%; P < 0.001
- Non-responders vs Delayed responders
- shorter event-free survival 38%; P = 0.025
Further findings
HF hospitalization or death among 6-month non-responders, by 12-month trajectory · after 6 months · per_group values = share of non-responders
- HF hospitalization or death among 6-month non-responders, by 12-month trajectory — Outcomes diverged after 6 months
- P < 0.001
- HF hospitalization or death among 6-month non-responders, by 12-month trajectory — Deterioration group: shorter event-free survival
- 59%
- HF hospitalization or death among 6-month non-responders, by 12-month trajectory — Deterioration group: P
- P < 0.001
Predictors of delayed response
- Ischaemic aetiology, non-LBBB and lower baseline LVEF predicted delayed response
Original publication
Redefining response to cardiac resynchronization therapy: a post hoc analysis of the MORE-CRT MPP trial. Europace. Published 10 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it